Covered recipient · General Payments record
CAMI MILLICENT COWART
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,693.90
- Reported across 97 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $319.35 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $113.87 | 6 |
| Lilly USA, LLC | $59.61 | 3 |
| PFIZER INC. | $32.75 | 2 |
| Phathom Pharmaceuticals, Inc. | $29.17 | 1 |
| Astellas Pharma US Inc | $24.54 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.72 | 1 |
| Amgen Inc. | $18.47 | 1 |
| GlaxoSmithKline, LLC. | $17.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $18.47 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117532680 | CMS |
| Astellas Pharma US Inc | $24.54 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139496130 | CMS |
| GlaxoSmithKline, LLC. | $17.22 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116703846 | CMS |
| Lilly USA, LLC | $16.62 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135573608 | CMS |
| Lilly USA, LLC | $22.46 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135612120 | CMS |
| Lilly USA, LLC | $20.53 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135596370 | CMS |
| Novartis Pharmaceuticals Corporation | $23.72 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086763405 | CMS |
| Novo Nordisk Inc | $21.66 | 01/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100477884 | CMS |
| Novo Nordisk Inc | $20.44 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100340440 | CMS |
| Novo Nordisk Inc | $15.89 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100629961 | CMS |
| Novo Nordisk Inc | $18.00 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100516671 | CMS |
| Novo Nordisk Inc | $19.37 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100494539 | CMS |
| Novo Nordisk Inc | $18.51 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100367789 | CMS |
| PFIZER INC. | $15.76 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131023428 | CMS |
| PFIZER INC. | $16.99 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131328100 | CMS |
| Phathom Pharmaceuticals, Inc. | $29.17 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151157641 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.